Xenetic Biosciences (XBIO) Price & Analysis

Compare

306 Followers

XBIO Stock Chart & Stats

Day’s Range― - ―

52-Week Range$2.20 - $5.27

Previous CloseN/A

Volume4.73K

Average Volume (3M)15.25K

Market Cap

$5.07M

Enterprise Value$1.27M

Total Cash (Recent Filing)$5.16M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta0.93

Next Earnings

Nov 14, 2025

EPS Estimate

-0.49

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.45

Shares Outstanding1,542,139

10 Day Avg. Volume11,613

30 Day Avg. Volume15,251

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.25

Enterprise Value/Revenue0.49

Enterprise Value/Gross Profit0.49

Enterprise Value/Ebitda-0.33

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusHold

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentXenetic's entry into clinical development for advanced pancreatic cancer with DNase I marks an important step in evaluating its potential in oncology.

PartnershipsThe renewed partnership with Scripps strengthens the pipeline and highlights ongoing potential in the translational development of DNase I.

Bears Say

Regulatory ChallengesThe collaboration with PeriNess Ltd. enhances the potential for regulatory approval and operational execution of DNase I studies in Israeli medical centers.

Xenetic Biosciences News

Xenetic reports Q2 EPS (45c) vs. (83c) last year

Reports Q2 revenue $589,897 vs. $726,404 last year. “We continue to set a strong foundation that we believe...

2M ago

XBIO

Xenetic Biosciences Reports Improved Financial Performance

Xenetic Biosciences, Inc. ( ($XBIO) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

XBIO

Is XBIO a Buy, Before Earnings?

Xenetic Biosciences, Inc. (XBIO) is scheduled to report 2nd quarter earnings on 08/08/2025. Regarding Q2 estimates, Wall Street...

2M ago

XBIO

Xenetic says PeriNess enters clinical study agreement for DNase Platform

Xenetic (XBIO) Biosciences announced that its collaboration partner, PeriNess, has entered into a Clinical Study Agreement to support...

2M ago

XBIO

Xenetic expands collaboration with The Scripps Research Institute

Xenetic (XBIO) Biosciences has continued its collaboration with The Scripps Research Institute to advance the development of the...

2M ago

XBIO

Xenetic says PeriNess reports Bnei Zion Medical Center commences patient dosing

Xenetic (XBIO) Biosciences announced that its collaboration partner, PeriNess, has informed the Company that Bnei Zion Medical Center...

3M ago

XBIO

Xenetic Biosciences Reports Improved Q1 2025 Results

Xenetic Biosciences, Inc. ( ($XBIO) ) has released its Q1 earnings. Here is a breakdown of the information...

4M ago

XBIO

Xenetic reports Q1 EPS (59c) vs. (78c) last year

Reports Q1 revenue $593,261 vs.$510,817 last year. “We remain focused on engaging with our strategic partners to participate...

5M ago

XBIO

Xenetic partner PeriNess enters clinical study agreement for XBIO-015

Xenetic (XBIO) Biosciences’ collaboration partner, PeriNess has entered into a Clinical Study Agreement to support an exploratory clinical...

6M ago

XBIO

Xenetic: PeriNess in XBIO-015 study to treat osteosarcoma and Ewing sarcoma

Xenetic (XBIO) Biosciences, announced that its collaboration partner, PeriNess has entered into a Clinical Study Agreement to support...

6M ago

XBIO

Xenetic reports FY24 EPS ($2.57) vs. ($2.71) last year

Reports FY24 revenue $2.5M vs. $2.54M last year. “Over the course of 2024, our team made notable advancements...

7M ago

XBIO

Xenetic presents preclinical data on DNase I with CAR T cells in murine model

Xenetic (XBIO) Biosciences announced the presentation of preclinical data investigating the potential of co-administration of deoxyribonuclease I with...

7M ago

XBIO

Xenetic extends research collaboration with University of Virginia

Xenetic (XBIO) Biosciences has extended its previously announced Research Funding Agreement with the University of Virginia to advance...

10M ago

XBIO

Xenetic Biosciences Expands Collaboration for Cancer Treatment

Xenetic Biosciences ( ($XBIO) ) just unveiled an update. Xenetic Biosciences has extended its collaboration with The Scripps...

11M ago

XBIO

XBIO FAQ

What was Xenetic Biosciences’s price range in the past 12 months?

Xenetic Biosciences lowest stock price was $2.20 and its highest was $5.27 in the past 12 months.

What is Xenetic Biosciences’s market cap?

Xenetic Biosciences’s market cap is $5.07M.

When is Xenetic Biosciences’s upcoming earnings report date?

Xenetic Biosciences’s upcoming earnings report date is Nov 14, 2025 which is in 41 days.

How were Xenetic Biosciences’s earnings last quarter?

Xenetic Biosciences released its earnings results on Aug 13, 2025. The company reported -$0.45 earnings per share for the quarter, beating the consensus estimate of -$0.64 by $0.19.

Is Xenetic Biosciences overvalued?

According to Wall Street analysts Xenetic Biosciences’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Xenetic Biosciences pay dividends?

Xenetic Biosciences does not currently pay dividends.

What is Xenetic Biosciences’s EPS estimate?

Xenetic Biosciences’s EPS estimate is -0.49.

How many shares outstanding does Xenetic Biosciences have?

Xenetic Biosciences has 1,542,139 shares outstanding.

What happened to Xenetic Biosciences’s price movement after its last earnings report?

Xenetic Biosciences reported an EPS of -$0.45 in its last earnings report, beating expectations of -$0.64. Following the earnings report the stock price went up 7.168%.

Which hedge fund is a major shareholder of Xenetic Biosciences?

Currently, no hedge funds are holding shares in XBIO

Company Description

Xenetic Biosciences

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

Xenetic Biosciences (XBIO) Earnings & Revenues

Historic Earnings Reports

XBIO Stock 12 Month Forecast

Average Price Target

―

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"NaN":"―"}},"plotLines":[{"color":"rgba(0,0,0,0)","label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[null,null,null,null,null],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.22,2.9723076923076923,2.724615384615385,2.476923076923077,2.229230769230769,1.9815384615384617,1.7338461538461538,1.4861538461538462,1.2384615384615385,0.9907692307692306,0.7430769230769232,0.4953846153846153,0.24769230769230743,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.3,"date":1682899200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.97,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.35,"date":1709251200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.14,"date":1714521600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.25,"date":1722470400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.1,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.2,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.99,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.92,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.46,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.73,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.75,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.22,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >